State Of Wyoming Karyopharm Therapeutics Inc. Transaction History

State Of Wyoming

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.58 $30,778 - $55,897	35,378 Added 74.78%	82,685 $71,000
Q1 2024 May 13, 2024	BUY	$0.72 - $1.66 $13,590 - $31,334	18,876 Added 66.39%	47,307 $71,000
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.31 $8,370 - $16,126	-12,310 Reduced 30.22%	28,431 $24,000
Q3 2023 Nov 14, 2023	BUY	$1.14 - $1.81 $46,444 - $73,741	40,741 New	40,741 $54,000
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $27,696 - $66,226	11,168 Added 188.84%	17,082 $58,000
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $19,143 - $27,307	-4,692 Reduced 44.24%	5,914 $32,000
Q2 2022 Aug 15, 2022	SELL	$4.15 - $8.37 $18,716 - $37,748	-4,510 Reduced 29.84%	10,606 $48,000
Q1 2022 May 13, 2022	BUY	$5.91 - $14.38 $4,071 - $9,907	689 Added 4.78%	15,116 $111,000
Q4 2021 Feb 11, 2022	BUY	$5.21 - $8.61 $4,819 - $7,964	925 Added 6.85%	14,427 $93,000
Q3 2021 Feb 11, 2022	SELL	$4.45 - $10.63 $4,009 - $9,577	-901 Reduced 6.26%	13,502 $79,000
Q2 2021 Feb 11, 2022	BUY	$8.11 - $11.11 $116,808 - $160,017	14,403 New	14,403 $149,000

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $51.1M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.